The estimated Net Worth of David Y Liu is at least $9.49 Milión dollars as of 16 November 2022. David Liu owns over 100,479 units of Protagonist Therapeutics Inc stock worth over $7,506,356 and over the last 8 years he sold PTGX stock worth over $786,514. In addition, he makes $1,199,600 as Chief Scientific Officer a Head of Research & Development at Protagonist Therapeutics Inc.
David has made over 13 trades of the Protagonist Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 100,479 units of PTGX stock worth $232,106 on 16 November 2022.
The largest trade he's ever made was exercising 100,479 units of Protagonist Therapeutics Inc stock on 16 November 2022 worth over $232,106. On average, David trades about 7,594 units every 103 days since 2016. As of 16 November 2022 he still owns at least 167,590 units of Protagonist Therapeutics Inc stock.
You can see the complete history of David Liu stock trades at the bottom of the page.
Dr. David Y. Liu Ph.D. serves as Chief Scientific Officer, Head of Research & Development of the Company. Dr. Liu has served as the Company's Chief Scientific Officer since May 2013 and has served as Chief Scientific Officer and Head of Research and Development since February 2016. Prior to Protagonist, Dr. Liu was the Chief Operating Officer and a cofounder of Trenovus, Inc., from 2010 to 2012. Prior to Trenovus, Dr. Liu was Vice President of Research at FibroGen Inc., from 2002 to 2010. Prior to FibroGen, Dr. Liu served as Director of Inflammation Research at Scios, Inc., now part of Johnson & Johnson, from 1992 to 2002. Dr. Liu held a position as an academic researcher at Brigham and Women's Hospital, Harvard Medical School and was Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, from 1976 to 1986. Dr. Liu received his Ph.D. in microbiology and immunology from Michigan State University, and his B.S. in Chemistry from The University of Chicago.
As the Chief Scientific Officer a Head of Research & Development of Protagonist Therapeutics Inc, the total compensation of David Liu at Protagonist Therapeutics Inc is $1,199,600. There are 2 executives at Protagonist Therapeutics Inc getting paid more, with Dinesh Patel having the highest compensation of $1,948,340.
David Liu is 69, he's been the Chief Scientific Officer a Head of Research & Development of Protagonist Therapeutics Inc since 2016. There are 2 older and 17 younger executives at Protagonist Therapeutics Inc. The oldest executive at Protagonist Therapeutics Inc is Dr. David Y. Liu, 71, who is the Chief Scientific Officer and Head of Discovery & Pre-Clinical Devel..
David's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160.
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson... a X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include: